Biosafety and Efficacy Studies of Colchicine‐Encapsulated Liposomes for Ocular Inflammatory Diseases
Authors:
- 31 January 2025
- journal article
- research article
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 113 (2) , e35540
Abstract
Inflammation is a critical component in the progression of various ocular diseases, such as age‐related macular degeneration, diabetic retinopathy, and uveitis, leading to significant vision loss. Colchicine has been used for treating gout with its anti‐inflammatory effect. However, free colchicine demonstrated cytotoxicity to ocular cells and cannot directly be used for eye disease. Thus, this study introduces, for the first time, the development and use of colchicine‐encapsulated liposomes as a novel therapeutic approach for managing inflammation‐driven ocular conditions. The encapsulation of colchicine within liposomes represents a significant innovation, aimed at enhancing biocompatibility and therapeutic efficacy while minimizing cytotoxic effects associated with free colchicine. Our research synthesized colchicine‐loaded liposomes and assessed their therapeutic impact on human monocytes, macrophages, and retinal pigment epithelium (RPE) cells in an inflammatory environment. The findings reveal a groundbreaking improvement in treatment strategies, with a substantial reduction in TNF‐alpha‐induced reactive oxygen species (ROS) and nitric oxide (NO) production in RPE cells. Moreover, the colchicine‐loaded liposomes significantly inhibited the proliferation and ROS production in activated monocytes and macrophages and effectively decreased interleukin (IL)‐1β and IL‐6 secretion, highlighting their strong anti‐inflammatory properties and showed slightly better suppression of these two cytokines than dexamethasone‐liposomes.Keywords
This publication has 39 references indexed in Scilit:
- Comparative study of cyclosporine A liposomes and emulsions for ophthalmic drug delivery: Process optimization through response surface methodology (RSM) and biocompatibility evaluationColloids and Surfaces B: Biointerfaces, 2023
- Synthesis, bioactive properties, and biomedical applications of intrinsically therapeutic nanoparticles for disease treatmentChemical Engineering Journal, 2022
- Therapeutic hydrogel sheets programmed with multistage drug delivery for effective treatment of corneal abrasionChemical Engineering Journal, 2022
- Colchicine-Containing Nanoparticles Attenuates Acute Myocardial Infarction Injury by Inhibiting InflammationCardiovascular Drugs and Therapy, 2021
- The role of the inflammasomes in the pathogenesis of uveitisExperimental Eye Research, 2021
- Multifunctional glutathione-dependent hydrogel eye drops with enhanced drug bioavailability for glaucoma therapyChemical Engineering Journal, 2020
- Recent developments in liposomal drug delivery systems for the treatment of retinal diseasesDrug Discovery Today, 2019
- Intraocular Pressure Effects of Common Topical Steroids for Post-Cataract Inflammation: Are They All the Same?Ophthalmology and Therapy, 2013
- Management of Diabetic RetinopathyJAMA, 2007
- Blood-retinal barrier permeability and its relation to progression of retinopathy in patients with type 2 diabetes. A four-year follow-up studyGraefe's Archive for Clinical and Experimental Ophthalmology, 1993